Clinical trials (12 555)

Go to page

assignment

person_addRecruitingIPhase I

Phase 1/2 Open‑Label Study of VS‑7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and Combination Therapy in Patients with Advanced KRAS G12D‑Mutant Solid Tumors

A Coruna Galicia, Spain

Countries

Interventions

Carboplatin

Sponsors

Verastem Inc.

assignment

scheduleNot Yet RecruitingIIIPhase III

Phase 3 Randomized Double‑Blind Placebo‑Controlled Study of Engasertib 40 mg QD for Reducing Epistaxis Frequency in Moderate‑to‑Severe Hereditary Hemorrhagic Telangiectasia

Angers, France

Countries

Sponsors

Vaderis Therapeutics AG

assignment

scheduleNot Yet RecruitingIPhase I

A Phase II Study of REGN9220 Combined with Odronextamab in Relapsed/Refractory Aggressive B‑Cell Non‑Hodgkin Lymphoma in Adults

Ghent, Belgium

Countries

Sponsors

Regeneron Pharmaceuticals Inc.

assignment

scheduleNot Yet RecruitingIIIPhase III

Effect of Perioperative Ketoprofen Suppression on Chronic Postoperative Pain after Video-Assisted Thoracic Surgery: Randomized Controlled Trial

Dijon, France

Countries

Interventions

Ketoprofen

Sponsors

Les Hopitaux Universitaires De Strasbourg

assignment

person_addRecruitingIIPhase II

Randomized, double‑blind, dose‑finding study of once‑weekly subcutaneous UBT251 versus semaglutide in adults with type 2 diabetes inadequately controlled on metformin ± SGLT2 inhibitor

Amberg, Germany

Countries

Interventions

Semaglutide

Sponsors

Novo Nordisk A/S

assignment

scheduleNot Yet RecruitingIIPhase II

Safety and Tolerability of Subcutaneous Lebrikizumab in Newly Diagnosed Bullous Pemphigoid: An Investigator-Initiated Multicenter Open-Label Proof‑of‑Concept Study

Aarhus, Denmark

Countries

Interventions

Lebrikizumab

Sponsors

Region Midtjylland

assignment

scheduleNot Yet RecruitingI/IIPhase I/II

Phase 1/2 Open‑Label Study of Intracochlear SENS‑601 Injection (SPHYNX System) in Pediatric Patients with GJB2‑Related Biallelic Hearing Loss

Paris, France

Countries

Sponsors

Sensorion

assignment

scheduleNot Yet RecruitingIIPhase II

Phase II Randomized Study of Tirzepatide with or without Letrozole Versus Standard Surgery in Postmenopausal Hormone Receptor‑Positive Breast Cancer

Leuven, Belgium

Countries

Interventions

Letrozole

Sponsors

UZ Leuven

assignment

scheduleNot Yet RecruitingIIPhase II

In‑vivo Fluorescence Molecular Bronchoscopy of Durvalumab‑680LT Distribution in Unresectable Stage III NSCLC After Chemoradiation

Groningen, The Netherlands

Countries

Interventions

Durvalumab

Sponsors

Universitair Medisch Centrum Groningen

assignment

scheduleNot Yet RecruitingIIPhase II

Phase II Randomized Open‑Label Study of Sacituzumab Govitecan versus Investigator’s Choice Combination Therapy in Relapsed/Refractory Cancer of Unknown Primary

Augsburg, Germany

Countries

Interventions

Calcium Folinate

Sponsors

Universitaetsklinikum Heidelberg AöR

assignment

scheduleNot Yet RecruitingIIIPhase III

Phase III Randomized Study of Single‑Administration AZD0120 BCMA/CD19 CAR‑T vs Continuous Standard Therapy in Transplant‑Ineligible Newly Diagnosed Multiple Myeloma

Aarhus, Denmark

Countries

Interventions

AZD0120

Sponsors

AstraZeneca AB

assignment

person_addRecruitingIPhase I

Randomized, Placebo‑Controlled, Dose‑Escalation Study of MOPEVAC‑Las Vaccine for Safety, Immunogenicity, and Optimal Dose in Healthy Adults

Paris, France

Countries

Sponsors

Institut Pasteur

assignment

scheduleNot Yet RecruitingIIIPhase III

Randomized, Double‑Blind, Multi‑Center Trial of Topical (S)-Ibuprofen (Dexibuprofen) Gel 5% versus Placebo for Pain Relief in Acute Soft‑Tissue Contusions

Bonn, Germany

Countries

Interventions

Dexibuprofen

assignment

scheduleNot Yet RecruitingIIPhase II

Randomized, Double‑Masked, Vehicle‑Controlled Study of Intranasal Cenegermin for Visual Acuity Improvement in Adults with Non‑Arteritic Anterior Ischemic Optic Neuropathy

Aarhus, Denmark

Countries

Interventions

Cenegermin

Sponsors

Dompe' Farmaceutici S.p.A.

assignment

scheduleNot Yet RecruitingIPhase I

A Phase I, Open‑Label, Dose‑Escalation Study Evaluating the Safety and Tolerability of BI 4060107 in Patients With Advanced Solid Tumors

Villejuif, France

Countries

Go to page

Looking for deeper trial context?

Investigator involvement, centre context, regional background — we can pull it together.

Clinical trials (12 555)

Looking for deeper trial context?

Clinical trials (12 555)